Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Biodexa Pharmaceuticals Plc American Depositary Receipt(BDRX US)

$3.69+0.308.97%Ext:$3.53-0.164.44%(Pre-Market · 08:00:43 UTC)
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
BDRX US​
Ask AI

SEC Filings

Financials(14)

Expand
  • 20-FFY 2025ended 31 Dec 202527 Mar
  • 20-FFY 2024ended 31 Dec 202411 Apr 2025
  • 20-FFY 2023ended 31 Dec 202319 Apr 2024
  • 20-F/AFY 2022ended 31 Dec 20225 May 2023
  • 20-FFY 2022ended 31 Dec 202228 Apr 2023
  • 20-FFY 2021ended 31 Dec 202126 Apr 2022
  • 20-FFY 2020ended 31 Dec 202030 Apr 2021
  • 20-F/AFY 2019ended 31 Dec 201917 Jun 2020
  • 20-FFY 2019ended 31 Dec 201915 Jun 2020
  • 20-F/AFY 2018ended 31 Dec 201828 May 2019
  • 20-FFY 2018ended 31 Dec 201830 Apr 2019
  • 20-FFY 2017ended 31 Dec 201724 Apr 2018
  • 20-FFY 2016ended 31 Dec 20166 Apr 2017
  • 20-FFY 2015ended 31 Dec 201514 Apr 2016

Events(272)

Expand
  • 6-KCurrent report (foreign private issuer)14 Oct
  • 6-KCurrent report (foreign private issuer)8 Oct
  • 6-KCurrent report (foreign private issuer)15 Sep
  • 6-KCurrent report (foreign private issuer)11 Sep
  • 6-KCurrent report (foreign private issuer)29 Jul
  • 6-KCurrent report (foreign private issuer)9 Jul
  • 6-K/AAMENDMENT NO. 130 Jun
  • 6-KCurrent report (foreign private issuer)30 Jun
  • 6-KCurrent report (foreign private issuer)30 Jun
  • 6-KCurrent report (foreign private issuer)17 Jun
  • 6-KCurrent report (foreign private issuer)14 May
  • 6-KCurrent report (foreign private issuer)27 Mar
  • 6-KCurrent report (foreign private issuer)18 Mar
  • 6-KCurrent report (foreign private issuer)4 Feb
  • 6-KCurrent report (foreign private issuer)6 Jan

Insider Ownership(6)

Expand
  • 3Parker Stephen Barry20 Mar
  • 3Merchant Ann Louise18 Mar
  • 3Stamp Stephen Anthony18 Mar
  • 3de Vries Simon18 Mar
  • 3Powell Fiona Mary18 Mar
  • 3Turton Simon18 Mar

Beneficial Ownership(31)

Expand
  • SC 13G/ABiodexa Pharmaceuticals Plc14 Aug
  • SC 13G/ABiodexa Pharmaceuticals Plc15 May
  • SC 13GBiodexa Pharmaceuticals Plc17 Feb
  • SC 13GBiodexa Pharmaceuticals Plc20 Jan
  • SC 13G/ABiodexa Pharmaceuticals Plc14 Nov 2025
  • SC 13GBiodexa Pharmaceuticals Plc18 Feb 2025
  • SC 13G/ABiodexa Pharmaceuticals Plc20 Nov 2024
  • SC 13G/ABiodexa Pharmaceuticals Plc14 Nov 2024
  • SC 13G/ABiodexa Pharmaceuticals Plc12 Nov 2024
  • SC 13G/ABiodexa Pharmaceuticals Plc7 Nov 2024
  • SC 13GBiodexa Pharmaceuticals Plc8 Aug 2024
  • SC 13GBiodexa Pharmaceuticals Plc23 Jul 2024
  • SC 13G/ABiodexa Pharmaceuticals Plc14 Feb 2024
  • SC 13G/ABiodexa Pharmaceuticals Plc14 Feb 2024
  • SC 13G/ABiodexa Pharmaceuticals Plc14 Feb 2024

Registrations(317)

Expand
  • 424B3333-27999413 Oct
  • 424B3PROSPECTUS SUPPLEMENT NO. 513 Oct
  • 424B3333-284350 PROSPECTUS SUPPLEMENT NO. 513 Oct
  • 424B3333-29747313 Oct
  • 424B3333-28148913 Oct
  • 424B3PROSPECTUS SUPPLEMENT NO. 513 Oct
  • 424B3PROSPECTUS SUPPLEMENT NO. 513 Oct
  • 424B3333-29910613 Oct
  • 424B3Prospectus filing (Rule 424(b)(3))6 Oct
  • F-1WARRANT INDUCEMENT24 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))15 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))15 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))15 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))15 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))15 Sep

Filing Review Correspondence(23)

Expand
  • CORRESPFiling review correspondence17 Dec 2025
  • CORRESPFiling review correspondence17 Dec 2025
  • CORRESPFiling review correspondence17 Nov 2025
  • CORRESPFiling review correspondence29 Sep 2025
  • CORRESPFiling review correspondence19 Aug 2025
  • DRSLTRFiling review correspondence (DRSLTR)1 May 2025
  • CORRESPFiling review correspondence23 Jan 2025
  • CORRESPFiling review correspondence15 Aug 2024
  • CORRESPFiling review correspondence11 Jun 2024
  • CORRESPFiling review correspondence20 Mar 2024
  • CORRESPFiling review correspondence15 Dec 2023
  • CORRESPFiling review correspondence15 Dec 2023
  • CORRESPFiling review correspondence23 Jun 2023
  • CORRESPFiling review correspondence25 May 2023
  • CORRESPFiling review correspondence16 Mar 2023

SEC Orders And Notices(40)

Expand
  • EFFECTNotice of effectiveness1 Oct
  • EFFECTNotice of effectiveness4 Aug
  • EFFECTNotice of effectiveness31 Mar
  • EFFECTNotice of effectiveness31 Mar
  • EFFECTNotice of effectiveness31 Mar
  • EFFECTNotice of effectiveness31 Mar
  • EFFECTNotice of effectiveness31 Mar
  • EFFECTNotice of effectiveness31 Mar
  • EFFECTNotice of effectiveness18 Dec 2025
  • EFFECTNotice of effectiveness24 Nov 2025
  • EFFECTNotice of effectiveness24 Nov 2025
  • EFFECTNotice of effectiveness30 Sep 2025
  • EFFECTNotice of effectiveness9 May 2025
  • EFFECTNotice of effectiveness9 May 2025
  • EFFECTNotice of effectiveness9 May 2025

Exempt Offerings(6)

Expand
  • D06b1 Aug 2024
  • D06b4 Jan 2024
  • D06b7 Jun 2023
  • D06b17 Feb 2023
  • D06b4 Jun 2020
  • D06b7 Nov 2019

Other(5)

Expand
  • SDSD26 May 2022
  • SDSD6 May 2020
  • SDSD14 May 2019
  • SDSD30 May 2018
  • CERTNASAUTO-GENERATED PAPER DOCUMENT3 Dec 2015